Aroa Biosurgery Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARX.AX research report →
Price Chart
About the company
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds.
- CEO
- Brian Ward
- IPO
- 2020
- Employees
- 273
- HQ
- Auckland, AU, NZ
Get TickerSpark's AI analysis on ARX.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $196.92M
- P/E
- 31.32
- Fwd P/E
- 46.19
- PEG
- 0.02
- P/S
- 1.43
- P/B
- 2.38
- EV/EBITDA
- 12.13
- Div Yield
- 0.00%
- Gross Margin
- 85.96%
- Op Margin
- 5.86%
- Net Margin
- 4.57%
- ROE
- 7.55%
- ROIC
- 8.19%
Latest fiscal year · YoY change
- Revenue
- $92.28M+19.9%
- Gross Profit
- $79.63M+20.7%
- Op Income
- $4.36M
- Net Income
- $4.16M+220.0%
- EPS
- $0.01+220.0%
- OCF Growth
- +501.9%
- FCF Growth
- +247.3%
- 52W High
- $0.80
- 52W Low
- $0.49
- 50D MA
- $0.59
- 200D MA
- $0.63
- Beta
- 0.85
- RSI (14)
- 46
- Avg Volume
- 302.21K
No earnings-call transcripts are available for ARX.AX yet.
- Free Float
- 75.3%
- Shares Outstanding
- 345.47M
- Float Shares
- 260.13M
Our ARX.AX coverage
Recent articles, reports, and earnings notes.
No research on ARX.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARX.AX report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.